https://www.selleckchem.com/pr....oducts/ziritaxestat.
Analysis was solely descriptive. Results The survey highlighted key areas of uncertainty in dyslipidaemia management in the four countries. These related to LDL-C targets in different patient groups, the safety of low LDL-C levels, the safety of statins, especially for effects on cognitive, renal and hepatic function and for haemorrhagic stroke risk, and lipid management strategies in patients with chronic kidney disease, including those with concomitant hypertriglyceridaemia. Conclusions This survey of physicians in Japan, Germany
Like
Comment
Share
